Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization

Inclusion Criteria: * Agreement to comply with safety guidelines to minimize contamination risks to COVID-19; * Agreement to perform a molecular test to detect COVID-19 to enter the study; * Healthy participants; * Non-injured skin in the test region; * Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations; * ability to consent to participation in the study; * Age from 18 to 59 years; * Phototype (Fitzpatrick): I to IV; * All sex. Exclusion Criteria: * Participants who belong to the risk group for COVID-19, that is, with diabetes, with chronic cardiovascular, renal and respiratory problems, immunosuppressed or other conditions that the doctor deems to belong to the risk group; * Pregnant or breastfeeding women; * Skin marks in the experimental area that interfere with the evaluation of possible skin reactions; * Active dermatoses; * Background of allergic reactions, irritation or intense discomfort sensations to topical use products; * History of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.); * Sensation of discomfort with temperature changes (too hot/very cold) and/or when in the air conditioning; * Participants with a history of allergy to materials used in the study; * History of pathologies aggravated or triggered by ultraviolet radiation; * Carriers of immunodeficiencies; * Intense sun exposure or tanning session up to 15 days before the initial evaluation; * Prediction of intense sun exposure or tanning session during the course of the study; * Expected to bathe in the sea, pool or bathtub during the conduct of the study; * Participants who practice water sports; * Dermography; * Aesthetic and/or body dermatological treatment until 03 weeks before the selection; * Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids until 2 weeks before selection or, considering deposit corticoids, the interval shall be 1 month before selection; * Treatment with acidic vitamin A and/or its derivatives via oral or topical up to 1 month before the start of the study; * Vaccination during the study or up to 3 weeks before the study; * Being or having participated in another clinical trial terminated less than 7 days before selection, if the previous trial is acceptable in use; * Being or having participated in another clinical trial terminated less than 21 days before the selection, in case the previous trial is compatible or Adverse Reaction investigative; * Any condition not mentioned above that, in the opinion of the investigator, may compromise the assessment of the trial; * History of no adherence or unwillingness to adhere to the study protocol; * Professionals directly involved in the conduct of this protocol and their families.